On the Record · Haemonetics
Haemonetics acquisitions, on the record
The businesses Haemonetics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
OpSens Inc.Word for word“On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired.” 10-K for 2024 | acquisition | December 12, 2023 | approximately $254.5 million |
Advanced Cooling Therapy, Inc., d/b/a Attune MedicalWord for word“The Company acquired Attune Medical for total upfront consideration of $160.0 million.” 10-K for 2024 | acquisition | — | $160.0 million |
Whole Blood product line (Blood Center business), sold to GVS, S.p.AWord for word“On January 13, 2025, we completed the transaction with GVS for total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones.” 10-K for 2025 | divestiture | On January 13, 2025, we completed the transaction with GVS | total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration |
Advanced Cooling Therapy, Inc., d/b/a Attune Medical ("Attune Medical")Word for word“On April 1, 2024, we completed our acquisition of Attune Medica for total consideration of $187.7 million , which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustme nts.” 10-K for 2025 | acquisition | On April 1, 2024 | total consideration of $187.7 million |
OpSens Inc. ("OpSens")Word for word“On December 12, 2023, we completed our acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired.” 10-K for 2025 | acquisition | On December 12, 2023, we completed our acquisition of OpSens | total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired |
Sale of a manufacturing facilityWord for word“the gain realized on the sale of a manufacturing facility in the first quarter of fiscal 2025, partially offset by operating, transaction and integration costs related to recent acquisitions, increased amortization of acquired intangible assets and amortization of fair value inventory step-up.” 10-K for 2025 | divestiture | first quarter of fiscal 2025 | — |
Vivasure Medical LimitedWord for word“On January 9, 2026, we acquired all of the outstanding equity interests of Vivasure for a net purchase price of $164.4 million.” 10-K for 2026 | acquisition | On January 9, 2026 | $164.4 million |
Attune MedicalWord for word“On April 1, 2024, the Company completed its acquisition of Attune Medical for a net purchase price of $ 176.2 million, which included an upfront cash payment of $ 162.0 million, or $ 150.5 million net of $ 11.5 million cash acquired, the fair value of contingent consideration of $ 25.3 million, and $ 0.4 million of working capital adjustments.” 10-K for 2026 | acquisition | On April 1, 2024 | $ 176.2 million |
Whole Blood product line within Blood Center businessWord for word“In the fourth quarter of fiscal 2025, we completed the divestiture of the Whole Blood product line within our Blood Center business, allowing us to better align our resources to higher margin, higher growth opportunities.” 10-K for 2026 | divestiture | fourth quarter of fiscal 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2017-04-01 | — | $0 | — |
| 2018-03-31 | — | $9 million | — |
| 2019-03-30 | — | $0 | — |
| 2020-03-28 | — | $9.8 million | $259.8 million |
| 2021-04-03 | $434.8 million | $44.6 million | $259.8 million |
| 2022-04-02 | $2.5 million | $10.6 million | — |
| 2023-04-01 | $2.9 million | $850,000 | — |
| 2024-03-30 | $243.9 million | $1.5 million | $87.1 million |
| 2025-03-29 | $150.9 million | $43.3 million | $69.5 million |
| 2026-03-28 | $60.2 million | $0 | $50.5 million |
Deal filings since 2016
- 2024-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-05-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-10-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-01-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-08-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Haemonetics’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-05-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.